Eric Van Cutsem

10 ta ish

Sorbonne University

1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

   Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova +13

   MaqolaOAOchiq kirish20105 iqtibos

   ABIABI:AkademIndex/2026.other.192778

2. Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

   Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin +32

   MaqolaOAOchiq kirish20173 iqtibos

   ABIABI:AkademIndex/2026.other.011754

3. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

   Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena +20

   MaqolaOAOchiq kirish20133 iqtibos

   ABIABI:AkademIndex/2026.other.098698

4. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

   Axel Grothey, Eric Van Cutsem, Alberto Sobrero +17

   Maqola20123 iqtibos

   ABIABI:AkademIndex/2026.other.241897

5. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

   Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong +17

   MaqolaOAOchiq kirish20183 iqtibos

   ABIABI:AkademIndex/2026.other.241935

6. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

   Thierry André, Kai‐Keen Shiu, Tae Won Kim +18

   Maqola20203 iqtibos

   ABIABI:AkademIndex/2026.other.513933

7. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

   Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein +34

   MaqolaOAOchiq kirish20122 iqtibos

   ABIABI:AkademIndex/2026.other.237708

8. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

   Eric Van Cutsem, Fernando Rivera, Scott Berry +9

   MaqolaOAOchiq kirish20092 iqtibos

   ABIABI:AkademIndex/2026.other.237787

9. Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

   Talia Golan, Pascal Hammel, Michele Reni +16

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.596947

10. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

    Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón +15

    Maqola20182 iqtibos

    ABIABI:AkademIndex/2026.other.630172